‘Unprecedented’ EMA Response To COVID-19 Must Be Sustained
Post Approval Setting Matters Too, Says New Agency Head Emer Cooke
The agility, flexibility and transparency that the European Medicines Agency has adopted during the development and assessment of COVID-19 products will have to continue after treatments and vaccines are on the market, says the soon-to-be new head of the agency, Emer Cooke.
